FDA Highlights Hands-On Approach To China Inspections In Budget Plan
This article was originally published in The Tan Sheet
The budget request targets an increase in pharmaceutical programs’ budget authority to boost the number of FDA staff focused on China’s manufacturing. The proposed $10 million increase, including $5.6 million to be allocated toward manufacturing, provides for additional inspections, educational efforts and inspectors in China.
You may also be interested in...
At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.
FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.
FDA will need a bit of time to develop a comprehensive database of all the facilities that produce active pharmaceutical ingredients and finished dosage forms for the U.S. market as part of the proposed generic drug user fee program.